• Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection - (10/06/22)
   
  
• Projected Impact of Expanded Long-Acting Injectable PrEP Use Among Men Who Have Sex With Men on Local HIV Epidemics - (10/06/22)
   
  
• Provision of HIV pre-exposure prophylaxis to female patients seeking family planning services in the United States - (10/06/22)
   
  
• HIV and Cardiac End-Organ Damage in Women: Findings from an Echocardiographic Study Across the United States - (10/06/22)
   
  
• Earlier menopause is associated with higher risk of incident frailty in community-dwelling older women in England - (10/03/22)
   
  
• Lenacapavir: a first-in-class HIV-1 capsid inhibitor - (10/03/22)
   
  
• A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117 - (10/03/22)
   
  
• Causes and outcomes of hepatic fibrosis in persons living with HIV - (10/03/22)
   
  
• Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review - 2017 - (09/30/22)
   
  
More HIV Articles...
 

• HDV/HBV+ Immigrants in USA - (10/03/22)
   
  
• HDV Prevalence in USA - (10/03/22)
   
  
• High HDV rates Among PWID - (09/29/22)
   
  
• Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection - (09/29/22)
   
  
• HBV Meeting Paris: Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301 - (09/26/22)
   
  
More Hep D Articles...
 

• High HCV Death Rates in NYC; Estimating the Number of IDUs in the USA - (09/29/22)
   
  
• HCV Elimination; states failing efforts - (09/14/22)
   
  
• Letter to the Editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals - (08/17/22)
   
  
• CDC: Too Few People - 33% - Treated for Hepatitis C - Reducing Barriers Can Increase Treatment and Save Lives - (08/15/22)
   
  
• 30% of HCV+ Adults Start DAAs Within 360 Days - CDC - Low HCV Treatment Rates - Disparities Persist - (08/15/22)
   
  
• IAC: Putting HBV/HCV Testing and Treatment in HIV Clinics Has Benefits in Vietnam - Mark Mascolini - (08/03/22)
   
  
• Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection - (07/25/22)
   
  
More Hep C Articles...
 

• HBV Drug Pipeline - at HBV Intl Meeting 2022 Paris - (09/26/22)
   
  
• HBV Meeting Paris: Replicor expands efficacy and safety envelope in decompensated cirrhosis with compassionate use of subcutaneous REP 2139-Mg - (09/26/22)
   
  
• HBV Meeting Paris: Dose-Dependent Durability of Hepatitis B Surface Antigen Reductions Following Administration of a Single Dose of VIR-3434, an Investigational, Neutralizing Vaccinal Monoclonal Antibody - (09/26/22)
   
  
• VIR-2218 Plus VIR-3434 Combination Therapy Reduces Hepatitis B Virus Surface Antigen Levels In Vivo - (09/26/22)
   
  
• Pharmacokinetics of ATI-1428, a Novel Ultra-potent Capsid Assembly Modulator - (09/26/22)
   
  
• HBV Meeting Paris: Next-generation core inhibitors demonstrate increased potency and distinct biochemical properties compared to first-generation core inhibitors - (09/26/22)
   
  
• HBV Meeting Paris: Combination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse model - (09/26/22)
   
  
More Hep B Articles...
 

List not necessarily listed here in order of date being held.